What records are connected here?
- Evidence lanes
- 1
- Source years
- 4
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved3Evidence: Limited human dataBrain, nerves and sleep
Also called Selank acetate3
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), recorded in FDA’s substance registry and also known as TP-7.1,3 The only human study found in this review is a 2015 Russian study of 70 patients with anxiety disorders, in which selank was added to the tranquilizer phenazepam; its design and results can be checked only from its abstract.6 FDA lists selank acetate among compounding nominations that were withdrawn after FDA identified possible safety risks, and states that it lacks important information on its safety in people.3 No FDA approval is reported in the sources reviewed here, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,5
| What it is | A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.3 |
| Human evidence | One small Russian clinical study of selank added to phenazepam, reported in a Russian journal. FDA states that it lacks important information on selank’s safety in people.3,6 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Selank is a synthetic peptide of seven amino acids: threonine, lysine, proline, arginine, proline, glycine and proline. FDA’s substance registry records it as selank and TP 7.1
FDA’s compounding safety-risk page refers to it as selank acetate (TP-7).3
The authors of a 2017 rat study describe selank as an anxiety-reducing peptide whose action may resemble that of benzodiazepine drugs.2
That proposed mechanism comes from animal research; the FDA sources reviewed here do not describe how selank acts in people.2,3
A 2015 Russian study compared the tranquilizer phenazepam alone in 30 patients with phenazepam plus selank in 40 patients with anxiety-phobic, hypochondriac and somatoform disorders.6
The authors report that phenazepam took effect sooner on a depression and anxiety rating scale when selank was added, that side effects of phenazepam such as poor attention and memory, sedation and fatigue were reduced, and that quality of life improved.6
The study is small, tested selank only alongside phenazepam, and is reported in Russian; its abstract does not say how patients were assigned or whether they or the assessors knew which treatment they had.6
FDA states that it lacks important information regarding any safety issues raised by selank acetate given to humans.3
Evidence-strength label: Limited human data. How this label is assigned
None of the sources reviewed here reports an approval of selank by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.4,5
Whether selank on its own is effective for anxiety: the human study reviewed here added it to phenazepam, and its methods can be checked only from the abstract.6
Whether it is safe in people: FDA states that it lacks important safety information.3
Whether effects seen in rats would carry over to people.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Selank: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Selank are a bounded selection, not every registration or paper about Selank. For the years before Selank was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Selank as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Selank in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination. The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination. The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 16, 2026
A new property of the synthetic anxiolytic Selank and its derivatives.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
A new property of the synthetic anxiolytic Selank and its derivatives.↗Source date October 16, 2026Literature metadata · added November 16, 2026
Antiviral properties of structural fragments of the peptide Selank.↗Source date October 16, 2026Literature metadata · added November 16, 2026
Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia.↗Source date October 11, 2026PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
13 of 13 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.
PubMed lists PMID 15508574 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 18019011 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
13 with attributed title, venue, publication-date, and type metadata.
Selected records span December 17, 2018 to October 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 15508574 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20506839 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18197389 in Neuroscience and behavioral physiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-02 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 25371249 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, with publication-date metadata of 2014-11-05 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 28293190 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2017-02-28 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 31236882 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2019-06-24 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24450168 in Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova as Journal Article, with publication-date metadata of 2013 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18019011 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 30255741 in Protein and peptide letters as Journal Article, with publication-date metadata of 2018 (year precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19882898 in Voprosy virusologii as Journal Article, with publication-date metadata of 2009 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20919548 in Eksperimental'naia i klinicheskaia farmakologiia as Journal Article, with publication-date metadata of 2010-08 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 21609736 in Regulatory peptides as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-24 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Behavioural Neurology · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Official source · Source checked November 16, 2026